Weight-loss drugs create a new problem: many people stop taking them and struggle to keep the weight off. Fractyl Health aims to fill that gap with a one-time endoscopy procedure and a longer-lasting gene-therapy approach, but its story hinges on upcoming trial results and whether insurers and doctors embrace a new kind of treatment.Read more
A growing wave of people using weight-loss drugs may leave many looking for a longer-lasting way to keep the weight off, and Fractyl Health is building procedure-based and genetic options aimed at that gap. The upside depends on strong clinical results and smoother insurance and regulatory adoption, while competition from ever-better drugs and the company’s cash needs remain key watch-outs.Read more
Fractyl Health is building a one-time procedure and gene-therapy approach aimed at helping people keep weight off and manage type two diabetes after they stop popular weight-loss drugs. The big question is whether its lead procedure can prove it works long term, win insurance coverage, and scale across clinics before the company runs out of time and money.Read more
No trending discussion available.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
